Clinical Manufacturing Volume By Service Provider Category

By Industry Standard Research

When it comes to outsourced clinical manufacturing, respondents allocate the largest proportion of project volume to A combination of drug substance and drug product CDMOs (41%). Close behind, Global, Full-Service, One-Stop-Shop CDMOs account for 37% of survey participants’ clinical manufacturing project volume. Over the next three years, respondents anticipate shifting some project work from A combination of drug substance and drug product CDMOs to Global, Full-Service, One-Stop-Shop CDMOs, bringing that category of provider’s volume in line with respondents’ overall preference.